Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
We examined the effect of intravenously infused glucagon-like peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed breakfast, and on spontaneous energy intake at an ad libitum lunch. 20 young, healthy, normal-weight men participated in a placebo-controlled, randomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/ kg.h or saline) was started simultaneously with initiation of the test meals. Visual analogue scales were used to assess appetite sensations throughout the experiment and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced satiety and fullness compared with placebo (treatment effect: P < 0.03). Furthermore, spontaneous energy intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected significantly by the treatment (P < 0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig. 1) [17, 18].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Short-term studies have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) induce weight loss by promoting satiety and reducing hunger16–19.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1,7, 8”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [3]
In the citing paper
“GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,755
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Items 501–600 of 1,003
Nexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13420 · Cited by 51
Dossat, A. M., Bodell, L. P., Williams, D. L., Eckel, L. A., & Keel, P. K. (2014) · International Journal of Eating Disorders · doi:10.1002/eat.22264 · Cited by 57
“Delivery of GLP-1 reduces food intake and increases satiation in a dose-dependent manner in humans.(12) Furthermore, rodent studies have provided evidence that peripherally released GLP-1 plays a physiological role in satiation(13) and central GLP-1 receptors mediate nutrient-induced satiation.”
Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.
Jackson, S., Martin, T. S., Jones, J. D., Seal, D., & Emanuel, F. S. (2010) · PubMed · Cited by 74
Ceddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 53
A Glucagon-Like Peptide-1 Receptor Agonist and an Antagonist Modify Macronutrient Selection by Rats
Peters, C. T., Choi, Y.-H., Brubaker, P. L., & Anderson, G. H. (2001) · Journal of Nutrition · doi:10.1093/jn/131.8.2164 · Cited by 59
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
Knop, F. K., Hansen, K. B., & Knop, F. K. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s7004 · Cited by 64
“GLP-1 receptors are found in various regions of the brain 21 and when activated these are believed to promote feeling of satiety which in combination with GLP-1-induced inhibition of gastrointestinal motility (mediated through the vagus nerve 22 ) reduces food intake and body weight.”
Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability and in Vivo Potency
Sebokova, E., Christ, A. D., Wang, H., Sewing, S., Dong, J. Z., Taylor, J., Cawthorne, M. A., & Culler, M. D. (2010) · Endocrinology · doi:10.1210/en.2009-1459 · Cited by 51
Bajka, B. H., Pinto, A. M., Pérez‐Moral, N., Saha, S., Ryden, P., Ahn‐Jarvis, J. H., van der Schoot, A., Bland, C., Berry, S. E., Ellis, P. R., et al. (2022) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2022.12.008 · Cited by 53
Appetite control after weight loss: what is the role of bloodborne peptides?
Doucet, É., & Cameron, J. (2007) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h07-019 · Cited by 51
Liraglutide in the management of type 2 diabetes
Wajcberg, E., & Amarah, A. R. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s10180 · Cited by 54
Obesity Pharmacotherapy in Patients With Type 2 Diabetes
Kahan, S., & Fujioka, K. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0044 · Cited by 50
“A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.”
MethodRole of Incretin Axis in Inflammatory Bowel Disease
Duan, L., Rao, X., Braunstein, Z., Toomey, A. C., & Zhong, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01734 · Cited by 57
“Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.”
BackgroundMethodNew treatments in type 2 diabetes: a focus on the incretin‐based therapies
Barnett, A. H. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03396.x · Cited by 49
Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide
Dungan, K., & Buse, J. B. (2005) · Clinical Diabetes · doi:10.2337/diaclin.23.2.56 · Cited by 51
Thom, G., Dombrowski, S. U., Brosnahan, N., Algindan, Y. Y., Rosario Lopez-Gonzalez, M., Roditi, G., Lean, M. E. J., & Malkova, D. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-0568-9 · Cited by 49
“GLP-1 infusion enhances satiety and reduces energy intake [37] and brain imaging studies have demonstrated that higher GLP-1 concentration diminishes the reward”
BackgroundGlucagon, GLP-1 and Thermogenesis
González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143445 · Cited by 49
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Carlsson Petri, K. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0458-5 · Cited by 47
“GLP-1 also decreases appetite and energy intake [10].”
BackgroundSelf-citationPancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies
Meece, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167336 · Cited by 50
A view of obesity as a learning and memory disorder.
Davidson, T. L., Tracy, A. L., Schier, L. A., & Swithers, S. E. (2014) · Journal of Experimental Psychology Animal Learning and Cognition · doi:10.1037/xan0000029 · Cited by 56
Altered glucose metabolism after bariatric surgery: What's GLP-1 got to do with it?
Smith, E. P., Polanco, G., Yaqub, A., & Salehi, M. (2017) · Metabolism · doi:10.1016/j.metabol.2017.10.014 · Cited by 54
Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
Scott, R., Minnion, J., Tan, T., & Bloom, S. R. (2018) · Peptides · doi:10.1016/j.peptides.2018.04.008 · Cited by 48
Physiological mechanisms mediating aspartame-induced satiety
Hall, W. L., Millward, D. J., Rogers, P. J., & Morgan, L. (2003) · Physiology & Behavior · doi:10.1016/s0031-9384(03)00034-9 · Cited by 51
“CCK and glucagon-like peptide-1 (GLP-1) are widely believed to be important satiety peptides in human beings [2,9,12,17,30], and CCK has been shown to be secreted in response to large doses of phenylalanine [3].”
BackgroundNo effect of glucagon-like peptide-1 on short-term satiety and energy intake in man
Long, S. J., Sutton, J. A., Amaee, W. B., Giouvanoudi, A., Spyrou, N. M., Rogers, P. J., & Morgan, L. M. (1999) · British Journal of Nutrition · doi:10.1017/s0007114599000513 · Cited by 49
Elkind-Hirsch, K. E., Shaler, D., & Harris, R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107548 · Cited by 53
Nutrition and l and K-enteroendocrine cells
Gutierrez-Aguilar, R., & Woods, S. C. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32834190b5 · Cited by 47
RANGANATH, L., NORRIS, F., MORGAN, L., WRIGHT, J., & MARKS, V. (1999) · Clinical Science · doi:10.1042/cs0960335 · Cited by 47
Monnier, L., Schlienger, J.-L., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.002 · Cited by 47
Kaku, K., Rasmussen, M. F., Nishida, T., & Seino, Y. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00128.x · Cited by 47
Regulation of Energy Homeostasis via GPR120
Ichimura, A., Hara, T., & Hirasawa, A. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00111 · Cited by 53
Naessén, S., Carlström, K., Holst, J. J., Hellström, P. M., & Hirschberg, A. L. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.014837 · Cited by 54
Self-citationWerner, U. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.06.003 · Cited by 47
Hou, Y., Ernst, S. A., Heidenreich, K., & Williams, J. A. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00293.2015 · Cited by 47
“It has also been reported that GLP-1 and its mimetics exhibit cardioprotective effects (3, 29), inhibit gastrointestinal secretion and motility (27, 49), and regulate food intake and appetite (14, 43).”
BackgroundPrediabetes in Adolescents: Prevalence, Management and Diabetes Prevention Strategies
Esquivel-Zuniga, R., & DeBoer, M. D. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s284401 · Cited by 53
“gastric emptying, which has been associated with clear effects on post-prandial blood glucose excursions.(76)”
BackgroundDetailed characterization of incretin cell distribution along the human small intestine
Guedes, T. P., Martins, S., Costa, M. M., Pereira, S. S., Morais, T., Santos, A., Nora, M. C., & Monteiro, M. P. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2015.02.011 · Cited by 53
The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study
Stevens, J. E., Horowitz, M., Deacon, C. F., Nauck, M., Rayner, C. K., & Jones, K. L. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05198.x · Cited by 45
“18, 19 Studies using the specific GLP-1 receptor antagonist, exendin (9-39),”
Regulation of appetite to treat obesity
Kim, G. W., Lin, J. E., Valentino, M. A., Colón‐González, F., & Waldman, S. A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.3 · Cited by 56
Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
Christensen, M., & Knop, F. K. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0102-x · Cited by 47
“Furthermore, GLP-1 decreases gastrointestinal motility, which in combination with afferent signaling through the vagus nerve and activation of GLP-1 receptors (GLP-1Rs) in the central nervous system, promotes satiety and reduces food intake, thereby controlling body weight [10].”
BackgroundGastro-intestinal hormones GIP and GLP-1
Kieffer, T. J. (2004) · Annales d Endocrinologie · doi:10.1016/s0003-4266(04)95625-9 · Cited by 49
“Thus GLP-1 infusion dose-dependently reduces spontaneous energy intake in humans [24, 31], and repeated administration to rats yields weight loss [12, 53].”
BackgroundIncretin secretion stimulated by ursodeoxycholic acid in healthy subjects
Murakami, M., Une, N., Nishizawa, M., Suzuki, S., Ito, H., & Horiuchi, T. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-20 · Cited by 46
“Furthermore, bile acid sequestrants have been found to increase plasma GLP-1 levels in human and rodents (Chen et al. 2010; Shang et al. 2010; Garg et al. 2011; Suzuki et al. 2007).”
BackgroundCirculating Levels of Ghrelin and GLP-1 are Inversely Related During Glucose Ingestion
Djurhuus, C., Hansen, T. K., Gravholt, C. H., Ørskov, L., Hosoda, H., Kangawa, K., Jørgensen, J. O. L., Holst, J. J., & Schmitz, O. (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-33475 · Cited by 46
Self-citationMcIntyre, R. S., Alsuwaidan, M., Goldstein, B. I., Taylor, V. H., Schaffer, A., Beaulieu, S., & Kemp, D. E. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400108 · Cited by 45
“58 In a double-blind, placebo-controlled, 20-week trial, with open-label orlistat as an active comparator, participants taking liraglutide lost significantly more weight than did those taking placebo or orlistat.”
Anorexigenic Effects of GLP-1 and Its Analogues
Gallwitz, B. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_8 · Cited by 50
GPR120 agonism as a countermeasure against metabolic diseases
Cornall, L. M., Mathai, M. L., Hryciw, D. H., & McAinch, A. J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.021 · Cited by 50
Hamdy, O., & Yusof, B. N. M. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.010 · Cited by 67
Obesity: A Review of Pathogenesis and Management Strategies in Adult
Aktar, N., Qureshi, N. K., & Ferdous, H. S. (2017) · Delta Medical College Journal · doi:10.3329/dmcj.v5i1.31436 · Cited by 64
Jensen, P. B., Blume, N., Mikkelsen, J. D., Larsen, P. J., Jensen, H. I., Holst, J. J., & Madsen, O. D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci275 · Cited by 47
Self-citationKadowaki, T., & Kondo, K. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12092 · Cited by 44
Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice
Rotondo, A., Amato, A., Lentini, L., Baldassano, S., & Mulè, F. (2010) · Peptides · doi:10.1016/j.peptides.2010.09.028 · Cited by 49
Higgins, V., Asgari, S., Hamilton, J. K., Wolska, A. T., Remaley, A. T., Hartmann, B., Holst, J. J., & Adeli, K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz261 · Cited by 50
Self-citationKendall, D. M., Kim, D., & Maggs, D. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.385 · Cited by 45
Anxiogenic-like action of centrally administered glucagon-like peptide-1 in a punished drinking test
Møller, C. H., Sommer, W. H., Thorsell, A., Rimondini, R., & Heilig, M. A. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00223-8 · Cited by 45
“An inhibitory effect on feeding and drinking has been proposed for GLP-1 in both rat (Turton et al., 1996; Wang et al., 1998) and man (Flint et al., 1998).”
BackgroundGlucagon-like peptide 1 (GLP-1) and eating
Gutzwiller, J., Degen, L. P., Heuss, L. T., & Beglinger, C. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.04.019 · Cited by 44
Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes
Parsons, G. B., Souza, D. W., Wu, H., Yu, D., Wadsworth, S. G., Gregory, R. J., & Armentano, D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302842 · Cited by 45
Baraboi, E.-D., Smith, P., Ferguson, A. V., & Richard, D. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00326.2009 · Cited by 46
O'Harte, F. P. M., Mooney, M. H., Lawlor, A., & Flatt, P. R. (2000) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00214-7 · Cited by 47
“Various studies have suggested that tGLP-1 may have also the bene¢ts of increasing insulinindependent glucose disposal [16,17] and suppressing appetite and energy intake in humans [18].”
BackgroundGLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
“Early human studies, using intravenously infused physiological concentrations of the active form of the GLP-1 peptide (7-36 amide; see (14) for details of post-translational processing of glucagon gene products), reported reduced appetite and food intake (26, 27).”
Iepsen, E. W., Have, C. T., Veedfald, S., Madsbad, S., Holst, J. J., Grarup, N., Pedersen, O., Brandslund, I., Holm, J.-C., Hansen, T., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100006 · Cited by 43
Self-citationFlint, A., Kapitza, C., & Zdravkovic, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12108 · Cited by 42
“GLP-1 has been shown to reduce appetite and energy intake in humans [6,7].”
BackgroundSelf-citationVisvanathan, R. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.04.012 · Cited by 48
“Administration of GLP-1 to humans reduces food intake and increases feelings of fullness.(38) The”
BackgroundThe structure of wheat bread influences the postprandial metabolic response in healthy men
Eelderink, C., Noort, M. W. J., Sözer, N., Koehorst, M., Holst, J. J., Deacon, C. F., Rehfeld, J. F., Poutanen, K. S., Vonk, R. J., Oudhuis, L. A. A. C. M., et al. (2015) · Food & Function · doi:10.1039/c5fo00354g · Cited by 47
Self-citationGhrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis
Dong, C. X., & Brubaker, P. L. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.185 · Cited by 51
Counterregulation of insulin by leptin as key component of autonomic regulation of body weight
Borer, K. T. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.606 · Cited by 49
Perna, S., Rondanelli, M., Astrone, P., Grugnetti, A., Solerte, S. B., & Guido, D. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s97383 · Cited by 42
“Liraglutide has the ability to decrease blood glucose without causing hypoglycemia, and, at the same time, it has several other metabolic properties: 1) promoting and maintaining a substantial weight loss; 2) deceleration of the gastric emptying; and 3) inducing satiety, decreasing energy intake.(9,10) Niswender et al…”
Harada, K., Kitaguchi, T., Kamiya, T., Aung, K. H., Nakamura, K., Ohta, K., & Tsuboi, T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.788653 · Cited by 47
McElroy, S. L., Mori, N. N., Guerdjikova, A. I., & Keck, P. E. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2017.12.029 · Cited by 47
Sánchez‐Tapia, M., Hernández-Velázquez, I., Pichardo‐Ontiveros, E., Granados‐Portillo, O., Mariscal, A. G., Tovar, A. R., & Torres, N. (2020) · Nutrients · doi:10.3390/nu12041182 · Cited by 50
“GLP-1 in intestine increased in the groups fed BB, followed by BB + HF + S and C groups, and GLP-1 abundance was almost suppressed by the C + HF + S, indicating that consumption of BB could increase satiety, as has been demonstrated in humans [24].”
Jensen, S. B. K., Janus, C., Lundgren, J. R., Juhl, C. R., Sandsdal, R. M., Olsen, L. M., Andresen, A., Borg, S. A., Jacobsen, I. C., Finlayson, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32307-y · Cited by 42
Self-citationPharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 53
Liu, M.-J., Shin, S., Li, N., Shigihara, T., Lee, Y.-S., Yoon, J., & Jun, H. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300005 · Cited by 44
Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs
Nagell, C. F., Wettergren, A., Ørskov, C., & Holst, J. J. (2006) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520500408253 · Cited by 42
“Furthermore, GLP-1 may play a physiological regulatory role in controlling appetite and energy intake in humans [3,4].”
BackgroundSelf-citationKnecht, S., Ellger, T., & Levine, J. A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.09.003 · Cited by 59
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
Petersen, B., & Christensen (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s45379 · Cited by 42
“Furthermore, GLP-1 decreases gastrointestinal motility, which, in combination with afferent signaling through the vagus nerve and activation of GLP-1 receptors in the central nervous system, promotes satiety and reduces food intake, thereby controlling or even reducing body weight.(16,23) The delaying effect of GLP-1…”
Hoenig, M. E., Jordan, E. T., Ferguson, D. C., & de Vries, F. (2009) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2009.08.004 · Cited by 52
Pinelli, N., Berlie, & Hurren (2012) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s27528 · Cited by 41
GLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 42
“In fact, several studies have demonstrated that GLP-1 promotes satiety and suppresses energy intake both in animals [17, 65–68] and human subjects [63, 69–72].”
BackgroundHata, T., Mera, Y., Ishii, Y., Tadaki, H., Tomimoto, D., Kuroki, Y., Kawai, T., Ohta, T., & Kakutani, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176560 · Cited by 42
“Peripheral administration of GLP-1 has been known to reduce food intake in humans and other animals (Donahey et al., 1998; Flint et al., 1998; Verdich et al., 2001).”
BackgroundEelderink, C., Noort, M. W. J., Sözer, N., Koehorst, M., Holst, J. J., Deacon, C. F., Rehfeld, J. F., Poutanen, K. S., Vonk, R. J., Oudhuis, L. A. A. C. M., et al. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1156-6 · Cited by 46
“Besides their role as incretin hormones, GIP is involved in fat metabolism [8], and GLP-1 is involved in decreasing gastric emptying rate [9], suppression of glucagon [10], as well as increasing satiety [11], and, in rodents, preserving β-cell function [12].”
BackgroundSelf-citationHerzlinger, S., & Horton, E. S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.009 · Cited by 46
“subjects, and in people with diabetes, GLP-1 inhibits food intake and promotes satiety [12,13], often resulting in weight”
BackgroundShousha, S. A., Nakahara, K., Nasu, T., Sakamoto, T., & Murakami, N. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.01.007 · Cited by 45
Tews, D., Werner, U., & Eckel, J. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2008-1042426 · Cited by 43
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
Younes, A., Li, M., & Karboune, S. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2065659 · Cited by 48
“…favor the release of angiotensin converting enzyme inhibitory di-or tri-peptides and increase the anti-diabetic, anti-tumor properties of the cocoa products/by-products (Marseglia et al. 2019; Kumari et al. 2018; Preza et al. 2010; Flint et al. 1998; Addison and Aguilar 2011; Ryan et al. 2017).”
BackgroundLiraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder
McElroy, S. L., Guerdjikova, A. I., Blom, T. J., Mori, N. N., & Romo‐Nava, F. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001803 · Cited by 45
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 46
Functional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 42
Holst, J. J., & McGill, M. A. (2011) · Clinical Drug Investigation · doi:10.2165/11595370-000000000-00000 · Cited by 44
Self-citationA critical update on the l eptin‐melanocortin system
Lavoie, O., Michael, N. J., & Caron, A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15765 · Cited by 46
“…satiety, reduce food intake, and reduce body weight, leading to the use of GLP1R agonists for the treatment of obesity (Astrup et al., 2009; Blundell et al., 2017; Flint et al., 1998; Jastreboff et al., 2022; O'Neil et al., 2018; Pratley et al., 2018; Van Can et al., 2014; Verdich et al., 2001).”
BackgroundGlucagon-like peptide-1 inhibits voltage-gated potassium currents in mouse nodose ganglion neurons
gaisano, G. G., j. park, S., daly, D. M., & beyak, M. J. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01430.x · Cited by 40
Asmar, M., Bache, M., Knop, F. K., Madsbad, S., & Holst, J. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2133 · Cited by 39
“GLP-1 Action May Involve Amylin J Clin Endocrinol Metab, May 2010, 95(5):2367–2375”
BackgroundSelf-citationTomasik, P., Sztefko, K., & Starzyk, J. (2004) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2004.17.12.1623 · Cited by 40
Non‐endocannabinoid N‐acylethanolamines and 2‐monoacylglycerols in the intestine
Hansen, H. S., & Vana, V. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14175 · Cited by 40
“As GLP-1 has anorectic properties (Flint et al., 1998), and as i.p. injected OEA (5 mg·kg 1) can inhibit food intake and increase plasma levels of OEA approximately 14-fold after 30 min to approximately 190 nM (Gaetani et al., 2003), it raises the possibility that formation of a complex with…”
BackgroundBaggio, L., Adatia, F., Bock, T., Brubaker, P. L., & Drucker, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005119200 · Cited by 40
Finkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 44
Tramutola, A., Arena, A., Cini, C., Butterfield, D. A., & Barone, E. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1246183 · Cited by 38
Otten, J., Ryberg, M., Mellberg, C., Andersson, T., Chorell, E., Lindahl, B., Larsson, C., Holst, J. J., & Olsson, T. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0082 · Cited by 36
Self-citationMilliken, B. T., Elfers, C., Chepurny, O. G., Chichura, K. S., Sweet, I. R., Borner, T., Hayes, M. R., Jonghe, B. C. D., Holz, G. G., Roth, C. L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01783 · Cited by 41
Activity-induced GLP-1 release in lean and obese subjects
Adam, T. C., & Westerterp‐Plantenga, M. S. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.08.035 · Cited by 42
Dong, J. Z., Shen, Y., Zhang, J., Tsomaia, N., Mierke, D. F., & Taylor, J. E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01313.x · Cited by 38
“GLP-1 is derived from differential posttranslational processing of proglucagon in L-cells and is secreted in two forms: a 31-mer peptide, GLP-1(7-37), and a C-terminally amidated 30-mer, GLP-1(7-36)NH2 [8].”
BackgroundPosovszky, C., & Wabitsch, M. (2014) · Hormone Research in Paediatrics · doi:10.1159/000368898 · Cited by 47
Yanagimoto, A., Matsui, Y., Yamaguchi, T. F., Hibi, M., Kobayashi, S., & Osaki, N. (2022) · Nutrients · doi:10.3390/nu14235063 · Cited by 42
“Therefore, it is critical to understand the neural systems involved in the effects of GLP-1 analogs to reduce food intake and body weight [42,43].”
Background
Metadata
- Authors
- Flint, A., Raben, A., Astrup, A., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-01
- Volume
- 101
- Issue
- 3
- Pages
- 515-520
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508592
- OpenAlex
- W1975756049
- Cited by
- 1,402
- References
- 40
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 62 · 2023: 33 · 2022: 55 · 2021: 53 · 2020: 49 · 2019: 44 · 2018: 52 · 2017: 49 · 2016: 54 · 2015: 59 · 2014: 64 · 2013: 74 · 2012: 72
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, satiety, appetite, energy intake, insulin, glucagon, blood glucose, appetite regulation, intravenous infusion
- MeSH terms
- Adult, Appetite, Appetite Depressants, Appetite Regulation, Blood Glucose, Energy Intake, Glucagon, Humans, Insulin, Male, Pain Measurement, Peptide Fragments, Protein Precursors, Satiation, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.